Response of premature infants with severe respiratory failure to inhaled nitric oxide. Preemie NO Collaborative Group.
Elevated pulmonary vascular resistance is seen in premature infants with severe respiratory distress syndrome (RDS). Inhaled nitric oxide (NO) has been shown to decrease pulmonary vascular resistance and to improve oxygenation in some patients with respiratory failure. The purpose of this study was to determine whether premature infants with severe RDS would respond to inhaled NO with an improvement in oxygenation. Eleven premature infants (mean gestational age 29.8 weeks) with severe respiratory failure caused by RDS were treated with NO in four concentrations [1, 5, 10, 20 parts per million (ppm) NO] and with placebo (0 ppm NO). Arterial blood gas measurements were drawn immediately before and at the end of each of the 15-minute treatments and were used to determine the arterial/alveolar oxygen ratio (PaO2/PAO2). Ten of the 11 infants had a greater than 25% increase in PaO2/PAO2. Five of the 11 had a greater than 50% increase in PaO2/PAO2. Despite normal cranial ultrasound imaging prior to NO, 3 infants had intracranial hemorrhage (ICH) noted on their first ultrasound scan after this brief period of NO treatment, and 4 additional infants developed ICH later during their hospitalization. No infant had significant elevations of methemoglobin concentrations after the total 60-minute exposure to NO. NO may be an effective method of improving oxygenation in infants with severe RDS. The disturbing incidence of ICH in this small group of infants needs to be carefully evaluated before considering routine use or NO for preterm infants.
Van Meurs
K P
KP
Division of Neonatal and Developmental Medicine, Stanford University School of Medicine, California, USA.
Rhine
W D
WD
Asselin
J M
JM
Durand
D J
DJ
D000280:Administration, Inhalation; D001784:Blood Gas Analysis; D002543:Cerebral Hemorrhage / Q000000981:diagnostic imaging / Q000209:etiology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000209:etiology; D007231:Infant, Newborn; D007234:Infant, Premature; D009569:Nitric Oxide / Q000627:therapeutic use*; D012127:Respiratory Distress Syndrome, Newborn / Q000150:complications / Q000188:drug therapy*; D014463:Ultrasonography; D014692:Ventilation-Perfusion Ratio / Q000187:drug effects
D009569:Nitric Oxide